Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Managing treatment toxicity when administering immunotherapies in patients with metastatic UC

Enrique Grande • 22 Oct 2023
ESMO 2023
Genitourinary Cancer Urothelial Carcinoma

Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses how associated toxicities can be managed in patients receiving immunotherapies for the treatment of metastatic urothelial carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Enrique Grande

Current care and biomarker needs in first-line metastatic urothelial cancer
1:47
Current care and biomarker needs in first-line metastatic urothelial cancer
Enrique Grande • 19 Oct 2025
Novel strategies for the management of metastatic urothelial cancer
1:28
Novel strategies for the management of metastatic urothelial cancer
Enrique Grande • 19 Oct 2025
Novel ADCs for bladder cancer beyond enfortumab vedotin
1:57
Novel ADCs for bladder cancer beyond enfortumab vedotin
Enrique Grande • 19 Oct 2025
Evolving standards in first-line metastatic urothelial cancer
1:11
Evolving standards in first-line metastatic urothelial cancer
Enrique Grande • 19 Oct 2025

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals